Related Experiment Videos
Male breast cancer
1St. George's Hospital, London, UK.
International Journal of Fertility and Women'S Medicine
|January 7, 2005
Summary
Male breast cancer (MBC) is rare but increasing. BRCA2 gene mutations significantly raise lifetime risk, necessitating discussion of clinical presentation and treatment options.
Area of Science:
- Oncology
- Genetics
Background:
- Male breast cancer (MBC) accounts for less than 1% of all breast cancer diagnoses.
- The incidence of MBC has been observed to be increasing.
- Genetic predisposition, specifically BRCA2 mutations, confers a substantial lifetime risk (7%) for male breast cancer.
Purpose of the Study:
- To discuss the clinical presentation of male breast cancer.
- To describe the histological features of male breast cancer.
- To review the primary treatment modalities for male breast cancer.
Main Methods:
- Review of clinical and histological presentations of male breast cancer.
- Synthesis of current treatment strategies for male breast cancer.
Main Results:
- Male breast cancer, though rare, shows a rising incidence.
- BRCA2 carriers have a notable lifetime risk of developing male breast cancer.
- Understanding clinical and histological characteristics is crucial for management.
Conclusions:
- Male breast cancer requires specific attention due to its rising incidence and genetic links.
- Comprehensive review of clinical, histological, and treatment aspects is essential for healthcare providers.
- Further research into risk factors and targeted therapies for male breast cancer is warranted.